Foundayo (Orforglipron) vs. Compounded Semaglutide: What Is Each and How Do They Compare?

*Foundayo (orforglipron) is an FDA-approved medication made by Eli Lilly. Compounded semaglutide is not FDA-approved and is not the same as Ozempic, Wegovy, or any other brand-name semaglutide product. This article is for educational purposes only and does not constitute medical advice. Consult your licensed healthcare provider before starting or changing any medication. Individual results vary. Prescriva is a Management Services Organization (MSO) operated by Blue Oak Services LLC. Clinical services are provided by independently licensed providers in our partner network and are not provided by Prescriva directly.*

---

A new option entered the GLP-1 weight loss space in April 2026: orforglipron, sold under the brand name Foundayo by Eli Lilly. It is the first oral small-molecule GLP-1 receptor agonist approved by the FDA for chronic weight management, available at $149 per month through platforms like Amazon One Medical and Ro.

At the same time, compounded semaglutide remains a widely used weight loss medication, offered through telehealth platforms as a prescription injectable prepared by licensed compounding pharmacies.

If you are researching your options, you may be wondering how these two treatments compare. This article lays out what each one is, how they work, and where they differ, so you can have a more informed conversation with your healthcare provider.

What Is Foundayo (Orforglipron)?

Foundayo is the brand name for orforglipron, a GLP-1 receptor agonist developed by Eli Lilly and Company. The FDA approved it in April 2026 for chronic weight management in adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol.

Foundayo is a small-molecule compound, which is what makes it meaningfully different from most GLP-1 medications that came before it. Traditional GLP-1 therapies like semaglutide are peptide-based: large biological molecules that the digestive system would break down before they could be absorbed. That structural reality is why those medications require injections. Orforglipron is a compact, chemically synthesized molecule that the gut can absorb intact, making a once-daily pill possible.

Once absorbed, orforglipron binds to GLP-1 receptors throughout the body and activates the same core pathways: appetite suppression, slower gastric emptying, and improved blood sugar regulation. The downstream effects are similar to injectable GLP-1s, even though the mechanism of getting there is different.

Foundayo does not require fasting before taking it, which distinguishes it from the existing oral semaglutide tablet (Rybelsus), which requires a strict 30-minute pre-dose fasting window.

What the Evidence Shows for Orforglipron

The clinical trial program supporting Foundayo's approval includes both phase 2 and phase 3 data.

A phase 2 trial published in the *New England Journal of Medicine* in 2023 found that adults taking the highest dose of orforglipron lost approximately 14.7% of their body weight over 36 weeks, compared to 2.3% in the placebo group [1]. That result was comparable to what other GLP-1 medications have shown in similar timeframes.

The phase 3 program, known as the ATTAIN trials, built on that foundation. The ATTAIN-MAINTAIN study, published in *Nature Medicine* in May 2026, examined long-term weight loss maintenance. Adults who continued taking orforglipron maintained substantially greater weight reduction compared to those who transitioned to placebo, supporting its use as an ongoing treatment rather than a short-term course [2].

Foundayo is available by prescription only, through licensed healthcare providers.

---

What Is Compounded Semaglutide?

Compounded semaglutide is a prescription injectable medication prepared by licensed compounding pharmacies using semaglutide as the active pharmaceutical ingredient. It is not manufactured by Novo Nordisk and is not the same product as Ozempic or Wegovy.

Compounded semaglutide is not FDA-approved. This is not a fine-print disclaimer. It is a meaningful regulatory fact: the FDA has not reviewed compounded semaglutide formulations for safety, efficacy, or quality through the same approval process used for brand-name drugs. Compounding pharmacies operate under state pharmacy board oversight (503A pharmacies) or FDA inspection (503B outsourcing facilities), but that oversight is different from the drug approval framework.

Compounded semaglutide is administered as a subcutaneous (under-the-skin) injection, typically once per week. Dosing can be adjusted over time based on individual response and tolerance, which is a flexibility that compounded formulations allow that is not always possible with the fixed-dose packaging of brand-name medications.

*Compounded semaglutide is a weekly injectable medication prepared by licensed 503A compounding pharmacies.*

What the Evidence Shows for Semaglutide

The evidence base for semaglutide is extensive. The STEP 1 clinical trial, published in the *New England Journal of Medicine* in 2021, found that adults with obesity using semaglutide 2.4 mg weekly alongside lifestyle intervention lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group [3]. The STEP and SUSTAIN trial programs collectively enrolled tens of thousands of participants across multiple years and countries.

That trial data was generated using FDA-approved brand-name semaglutide, not compounded formulations. The regulatory standards for the branded and compounded versions differ, and trial results from branded products cannot be directly attributed to compounded preparations.

---

Key Differences at a Glance

Who Might Prefer an Oral GLP-1 Like Foundayo?

Some people have a significant aversion to needles. For those individuals, a once-daily pill removes what would otherwise be a persistent barrier to starting or staying on treatment. Foundayo also carries the full weight of FDA approval, which matters to patients who place high value on that regulatory status.

Foundayo's pricing at $149 per month makes it more accessible than brand-name injectable GLP-1s like Wegovy or Ozempic, which typically cost significantly more without insurance. For patients who want an FDA-approved option at a lower cash-pay price, the oral pill represents a genuinely new category.

The absence of an injection also simplifies the logistics of travel and daily routines. There is no refrigeration requirement for Foundayo, no sharps disposal, and no weekly injection to schedule.

Who Might Prefer Compounded Semaglutide?

Semaglutide's clinical track record spans more than a decade and includes large, long-term trials across populations with obesity, type 2 diabetes, and cardiovascular disease. Patients who feel reassured by that breadth of data, and by the pharmacology of semaglutide specifically, may prefer to continue with or start injectable semaglutide therapy.

Compounded formulations also offer dosing flexibility that fixed commercial products do not. A prescribing provider can adjust dose and titration schedule based on individual response, tolerance, and other medications, which some patients find valuable.

For people who have already been doing well on injectable semaglutide or who are familiar with the once-weekly routine, switching to a new molecule and a daily pill is not necessarily an upgrade. Stability and established response are their own form of value.

An Important Caveat: Neither Replaces Medical Judgment

Comparing these two medications on paper is a starting point, not a conclusion. Neither is universally better than the other, and neither is a substitute for an individualized assessment by a licensed healthcare provider.

A licensed provider will consider your medical history, current medications, BMI, comorbidities, and personal preferences before recommending any weight management medication. Individual response to GLP-1 therapies varies significantly: some people tolerate one medication well and struggle with another. Some achieve meaningful results quickly; others take longer to find the right dose and approach.

It is also worth noting that orforglipron is a new medication. Foundayo has strong phase 3 evidence supporting its approval, but the long-term safety record that exists for semaglutide, built over years of real-world use, does not yet exist for orforglipron. That is not a reason to avoid it, but it is context worth having.

---

The Bottom Line

Foundayo (orforglipron) and compounded semaglutide are both GLP-1 weight loss options with meaningful differences in how they work, how they are regulated, and how they are administered.

Foundayo is FDA-approved, taken as a daily oral pill, and priced at $149 per month. It is a genuinely new class of weight loss medication, supported by phase 3 clinical data.

Compounded semaglutide is not FDA-approved, administered as a weekly injection, and offers dosing flexibility through licensed compounding pharmacies. The broader semaglutide evidence base reflects data from FDA-approved branded formulations, not compounded preparations.

The right choice depends on your health history, preferences, and what your provider recommends for you specifically. If you are exploring GLP-1 treatment options, the best next step is a conversation with a licensed healthcare provider who can evaluate your full picture.

Prescriva connects you with independently licensed providers who can discuss whether a compounded GLP-1 program may be appropriate for your situation. [Get started here.](/start)

---

*This is not medical advice. Compounded medications are not FDA-approved. Consult a licensed healthcare provider before starting any new medication. Results vary by individual. Prescriva is a Management Services Organization (MSO). Clinical services are provided by independently licensed providers in our partner network.*

---

References

1. Wharton S, et al. Orforglipron for the treatment of obesity. *New England Journal of Medicine*. 2023;389(10):877-888. [https://pubmed.ncbi.nlm.nih.gov/37351564/](https://pubmed.ncbi.nlm.nih.gov/37351564/)

1. Aronne LJ, et al. Weight loss maintenance with orforglipron in adults with obesity (ATTAIN-MAINTAIN): a randomized, double-blind, placebo-controlled, phase 3b trial. *Nature Medicine*. 2026 May 13. [https://pubmed.ncbi.nlm.nih.gov/42120723/](https://pubmed.ncbi.nlm.nih.gov/42120723/)

1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. *New England Journal of Medicine*. 2021;384(11):989-1002. [https://pubmed.ncbi.nlm.nih.gov/33567185/](https://pubmed.ncbi.nlm.nih.gov/33567185/)